[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kaposiform-hemangioendothelioma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kaposiform-hemangioendothelioma":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100603063","phase-2-sirolimus-discontinuation-strategies-in-kaposiform-hemangioendothelioma-100603063",false,"NCT07131644","Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma","A Randomized Controlled Trial Comparing Three Sirolimus Discontinuation Strategies in Patients With Kaposiform Hemangioendothelioma","Inclusion Criteria:\n\n* KHE patients who have received sirolimus treatment and met the criteria for drug discontinuation.\n* With evaluable clinical or imaging parameters to monitor disease activity or recurrence.\n* Patients or their guardians are able to understand the study and provide written informed consent.\n* Hematologic and hepatic\u002Frenal function meet the safety criteria for drug administration.\n\nExclusion Criteria:\n\n* Patients who are unable to comply with the follow-up or treatment schedule, potentially affecting the integrity of study data.","ALL",{"count":18,"type":19},120,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","Sirolimus has demonstrated efficacy in the treatment of kaposiform hemangioendothelioma (KHE); however, a high rate of rebound growth following discontinuation has been reported, highlighting the clinical importance of establishing an appropriate withdrawal regimen.",[25],"Kaposiform Hemangioendothelioma",[25,27,28],"Sirolimus","Discontinuation Strategies","NOT_YET_RECRUITING","2025-09-01",{"date":32,"type":33},"2025-09-08","ACTUAL",{"date":35,"type":19},"2025-09-13",{"date":37,"type":19},"2028-02-01",{"name":39,"class":40},"West China Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":4,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100466245","the-effect-of-sirolimus-on-immunizations-during-the-treatment-of-kaposiform-hemangioendothelioma-100466245","NCT05351216","The Effect of Sirolimus on Immunizations During the Treatment of Kaposiform Hemangioendothelioma","The Effect of Sirolimus on Time-sequentially Scheduled Immunizations During the Treatment of Kaposiform Hemangioendothelioma: a Case-control Study","Inclusion Criteria:\n\n* Case groups:\n* KHE patients treated with sirolimus.\n* After immunoglobulin and flow cytometry assays, as well as outpatient evaluation and assessment, those participants will be vaccinated with live attenuated vaccines or inactivated vaccines in a timely order according to the advice.\n* Control groups:\n* Healthy children with no immune deficiencies.\n* Participants are vaccinated according to the National Immunization Program in a timely manner.\n* Participants are matched to the case group according to age.\n\nExclusion Criteria:\n\n* HBsAg, HBeAg positive, or other active infectious diseases;\n* History of immunodeficiency or low immunoglobulin levels;\n* Autoimmune disease or fever during blood collection;\n* Use of other medication or surgery;\n* Suffering from other bleeding disorders;\n* Suffering from other solid tumors or hematological tumors, etc.;\n* Withdraw informed consent.",true,"12 Years",{"count":52,"type":19},174,"OBSERVATIONAL","To research and explore the antibody protection and immune memory after vaccination in children with KHE during sirolimus administration. To explore the feasibility (safety and efficacy) of vaccination in a timely manner during the administration of sirolimus in children with KHE. To search for back-up plans for vaccination regimens for KHE patients taking sirolimus in children who do not respond to primary vaccination.",[25],[57,27],"Following National Vaccination Program","RECRUITING","2025-06-24",{"date":61,"type":33},"2025-06-27",{"date":63,"type":33},"2021-03-01",{"date":65,"type":19},"2028-03",{"name":67,"class":40},"Children's Hospital of Fudan University",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":77,"conditions":78,"keywords":85,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100285864","identification-of-biomarkers-for-patients-with-vascular-anomalies-100285864","NCT03001180","Identification of Biomarkers for Patients with Vascular Anomalies","Inclusion Criteria:\n\n* Any patient having labs drawn as standard of care will have blood drawn for the study if consented\u002F assented.\n* All patients who are undergoing a surgical procedure or sclerotherapy are currently consented for participation in the tissue bank.\n\nExclusion Criteria:\n\n* N\u002FA","1 Day",{"count":76,"type":19},1000,"The study will use blood (serum and plasma) and tissue obtained from participants undergoing prescribed surgical resection of vascular anomalies of interest proposed in this study. The study will also use blood (serum and plasma) and tissue collected and stored in a tissue bank maintained by the Department of Hematology\u002FOncology.",[79,80,25,81,82,83,84],"Vascular Anomaly","Generalized Lymphatic Anomaly","Kaposiform Lymphangiomatosis","Gorham-Stout Disease","Klippel Trenaunay Syndrome","Congenital Lipomatous Overgrowth, Vascular Malformations, and Epidermal Nevi",[80,79,25,81,86,87,88,89,90,91],"Vascular Endothelial Growth Factor","Biomarkers","GLA","KLA","KHE","GSD","2024-11-05",{"date":94,"type":33},"2024-11-06",{"date":96,"type":4},"2015-04",{"date":98,"type":19},"2050-12",{"name":100,"class":40},"Children's Hospital Medical Center, Cincinnati",2]